🇺🇸 FDA
Company

Outlook

Outlook Therapeutics

OTLK biotech USA

Quick answer

Outlook is a biotech company (OTLK) headquartered in ISELIN, NJ, USA with 2 tracked pipeline programs.

Pipeline (2)

project

bevacizumab

Age-related Macular Degeneration

Phase 3 · mab · active

4 trials project

bevacizumab

Neovascular Age-related Macular Degeneration

Phase 3 · mab · completed

1 trials

Patents (2)

patent

US 11285210

Buffer formulations for enhanced antibody stability

Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10376582

Buffer formulations for enhanced antibody stability

Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)